Technologies for licencing

Lipid nanoparticles for the treatment of dry eye disease


  • Sterile biocompatible and biodegradable nanoparticles (green synthesis).
  • Novel ocular delivery system with improved stability.
  • Sustained release of the nanoparticles (increased bioavailability).
  • Easy scale-up.

Benefits for patients

  • Dry eye curative and preventive effect.
  • Long-term effect: Moisturizing and calming prolonged action.
  • Other potential therapeutic effects: Anti-inflammatory, antibacterial and anti-microbial effects.


The group is looking for a license agreement, but other collaborations may be considered.

Intellectual Property

International Patent Application EP23382105.7
Priority date: February 6th 2023




Rosa Vázquez
Tel: +34 934 039639

Executive summary

The research group, with wide experience in nanostructured systems of controlled drug delivery generation and a demonstrated experience in the development of ophthalmologic applications, has generated an ophthalmic sterile solution containing green natural compounds with prolonged moisturizing effects.


Dry eye disease is a multifactorial disease of the ocular surface characterized by a loss of the homeostasis of the tear film. Hyperosmolarity, ocular surface damage, and inflammation play etiological roles. In Europe, there are 253M people affected (>60% more than 45y). First-line therapy is based on artificial tears in the form of eye drops, gel, or ointments. But some problems still need to be solved:

  • Artificial tears have no anti-inflammatory properties and do not deal with the principal pathogenesis of the disease.
  • Short ameliorating and moisturizing effect.
  • Treatments for ocular inflammation are corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs).
  • Prolonged use involves severe side effects (increasing ocular pressure and cataract formation).
  • In current formulations, less than 5% of the initial dose reaches the first eye layers.


The asset is an ophthalmic sterile solution in the form of artificial tears formed by second-generation nanostructured lipid carriers (NLCs) containing natural green compounds that confer prolonged moisturizing effects for the ocular surface as well as anti-inflammatory, anti-oxidant, and anti-microbial properties.

Current stage of development

NLC development, optimization and characterization, stability as well as in vivo and in vitro validation have been already carried out. A viability study and regulatory roadmap is already done. The technology is ready to be transferred.


Share this post:
Tags: Life Sciences, Health and Life Sciences


Utilitzem cookies de tercers amb finalitats tècniques i analítiques. Si continua navegant vol dir que accepta la nostra política de cookies. Més informació,plugin cookies política de cookies.

Aviso de cookies